{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:59:55Z","timestamp":1772704795435,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104692"],"award-info":[{"award-number":["82104692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2020CFB500"],"award-info":[{"award-number":["2020CFB500"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022020801020516"],"award-info":[{"award-number":["2022020801020516"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y-HR2019-0325"],"award-info":[{"award-number":["Y-HR2019-0325"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.intimp.2023.111176","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:39:12Z","timestamp":1699465152000},"page":"111176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"PB","title":["Clinical outcomes and immunological evaluation of toripalimab combination for cancer treatment: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-8160","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongda","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.111176_b0005","doi-asserted-by":"crossref","unstructured":"A. Ribas JDW. Cancer immunotherapy using checkpoint blockade, Science 359 (6382) (2018) 1350\u20131355.","DOI":"10.1126\/science.aar4060"},{"issue":"8","key":"10.1016\/j.intimp.2023.111176_b0010","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","article-title":"Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure)","volume":"27","author":"Kim","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2023.111176_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.111176_b0035","unstructured":"Administration NMP. Drug Approval Documents Released on November 26, 2021. Available at: https:\/\/wwwnmpagovcn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20211126160047176html (Accessed November 30, 2021). 2021."},{"key":"10.1016\/j.intimp.2023.111176_b0040","unstructured":"Administration. NMP. Drug Approval Documents Released on February 19, 2021. Available at: https:\/\/wwwnmpa govcn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20210219085955119html (Accessed November 30, 2021). 2021."},{"key":"10.1016\/j.intimp.2023.111176_b0045","unstructured":"ProductsAdministration NM. Drug Approval Documents Released on April 12, 2021. Available at: https:\/\/wwwnmpagovcn\/zwfw\/sdxx\/ sdxxyp\/yppjfb\/20210412090005190html (Accessed November 30, 2021). 2021."},{"issue":"5","key":"10.1016\/j.intimp.2023.111176_b0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: First Global Approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.intimp.2023.111176_b0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.22.00727","article-title":"Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.111176_b0060","article-title":"Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","author":"Wang","year":"2022403277","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.intimp.2023.111176_b0065","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0070","first-page":"114","article-title":"Clinical effect of toripalimab combined with concurrent chemoradiotherapy in the treatment of local advanced nasopharyngeal carcinoma","volume":"54","author":"Wang","year":"2023","journal-title":"Med. Sci. J. Central South China."},{"issue":"11","key":"10.1016\/j.intimp.2023.111176_b0075","first-page":"981","article-title":"Effect of toripalimab injection combined with NP chemotherapy in first line treatment of advanced NSCLC and the influence on changes of PD-L1 in peripheral blood lymphocytes","volume":"25","author":"Ran","year":"2023","journal-title":"Pract. Pharmacy Clin. Remedies."},{"issue":"4","key":"10.1016\/j.intimp.2023.111176_b0080","first-page":"585","article-title":"Efficacy of Toripalimab Combined with Platinum-based Doublet Chemotherapy in Non-small Cell Lung Cancer with TP Gene Mutation","volume":"38","author":"Hou","year":"2023","journal-title":"Prac. J. Cancer."},{"issue":"2","key":"10.1016\/j.intimp.2023.111176_b0085","first-page":"128","article-title":"Efficacy of TACE Combined with Sorafenib and Triripril in the Treatment of Advanced Primary Liver Cancer","volume":"30","author":"Peng","year":"2023","journal-title":"Clin. J. Integr. Trad. West Med. Di."},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0090","first-page":"54","article-title":"Effect of immunocheckpoint inhibitor combined with ranvartinib on TACE resistance to advanced primary liver cancer and its influence on serum PDGF and VEGF","volume":"22","author":"Di","year":"2023","journal-title":"Chin. J. Diffic. Compl. Cas."},{"issue":"19","key":"10.1016\/j.intimp.2023.111176_b0095","first-page":"123","article-title":"Effect of Toripalimab Combined with SOX Regimen Chemotherapy on Rehabilitation of Patients with Advanced Gastric Cancer","volume":"3","author":"Zhou","year":"2022","journal-title":"RARM."},{"issue":"2","key":"10.1016\/j.intimp.2023.111176_b0100","first-page":"128","article-title":"Clinical study of toripalimab injection combined with XP regimen in the treatment of advanced gastric cancer","volume":"30","author":"Song","year":"2022","journal-title":"Clin. J. Integr. Trad. West Med. Dig."},{"issue":"2","key":"10.1016\/j.intimp.2023.111176_b0105","first-page":"100","article-title":"Efficacy and safety of teriprizumab combined with bevacizumab in the treatment of metastatic MSI-H colorectal cancer above the second line","volume":"49","author":"Lin","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2023.111176_b0110","article-title":"Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with firstline chemotherapy for advanced NSCLC without EGFR\/ALK mutations","volume":"40","author":"Wang","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2023.111176_b0115","article-title":"Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma","volume":"82","author":"Mai","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2023.111176_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108790","article-title":"Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis","volume":"109","author":"Li","year":"2022","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2023.111176_b0125","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","article-title":"Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy","volume":"43","author":"Zhu","year":"2020","journal-title":"Cell. Oncol. (Dordr.)"},{"key":"10.1016\/j.intimp.2023.111176_b0130","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","article-title":"Combining chemotherapy with PD-1 blockade in NSCLC","volume":"186","author":"Mathew","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2023.111176_b0140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/imt-2022-0236","article-title":"Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis","volume":"15","author":"Zhang","year":"2023","journal-title":"Immunotherapy"},{"issue":"9","key":"10.1016\/j.intimp.2023.111176_b0145","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/hed.27452","article-title":"First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta-analysis and cost-effectiveness analysis","volume":"45","author":"Han","year":"2023","journal-title":"Head Neck"},{"issue":"8","key":"10.1016\/j.intimp.2023.111176_b0150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2023.111176_b0155","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/cam4.3718","article-title":"Safety and Efficacy of PD-1\/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis","volume":"10","author":"Geng","year":"2021","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0160","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.20.00290","article-title":"Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma","volume":"39","author":"McBride","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.111176_b0165","doi-asserted-by":"crossref","first-page":"1197698","DOI":"10.3389\/fonc.2023.1197698","article-title":"Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma","volume":"13","author":"Xie","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111176_b0170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","article-title":"PI3Kalpha\/delta inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity","volume":"6","author":"Carnevalli","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2023.111176_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2023.111176_b0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.intimp.2023.111176_b0185","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study","volume":"39","author":"Ian Chau","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2023.111176_b0190","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial","volume":"326","author":"Luo","year":"2021","journal-title":"J. Am. Med. Assoc."},{"issue":"10302","key":"10.1016\/j.intimp.2023.111176_b0195","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Jong-Mu Sun","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2023.111176_b0200","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2023.111176_b0205","first-page":"1","article-title":"Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis","volume":"109","author":"Zi-Chun Li","year":"2022","journal-title":"Int. Immunopharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923015023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923015023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:04:02Z","timestamp":1761588242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923015023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":41,"alternative-id":["S1567576923015023"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111176","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes and immunological evaluation of toripalimab combination for cancer treatment: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111176"}}